Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Beats Estimates By $1.66 EPS

Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings results on Thursday. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $1.66, FiscalAI reports. The business had revenue of $40.01 million for the quarter, compared to analysts’ expectations of $14.76 million. Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $9.36 on Friday. Keros Therapeutics has a 1 year low of $9.26 and a 1 year high of $22.55. The business’s 50 day moving average price is $11.18 and its 200-day moving average price is $11.92. The firm has a market capitalization of $185.61 million, a PE ratio of -3.32 and a beta of 1.13.

Keros Therapeutics declared that its board has authorized a share repurchase plan on Wednesday, September 9th that permits the company to repurchase $5 million in outstanding shares. This repurchase authorization permits the company to purchase up to 2.3% of its shares through open market purchases. Share repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the transaction, the insider owned 27,559 shares of the company’s stock, valued at $283,582.11. This trade represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 5,343 shares of company stock valued at $54,985. 12.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on KROS shares. Leerink Partners lowered their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, November 1st. Zacks Research upgraded Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $21.40.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.